Sana Biotechnology, Inc. (NASDAQ:SANA) Receives $8.17 Average Price Target from Analysts

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have been given a consensus recommendation of “Moderate Buy” by the nine ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $8.1667.

SANA has been the subject of a number of recent research reports. Wall Street Zen cut Sana Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. Zacks Research upgraded Sana Biotechnology from a “hold” rating to a “strong-buy” rating in a research note on Friday, January 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Sana Biotechnology in a report on Monday, December 29th. Wedbush boosted their target price on shares of Sana Biotechnology from $5.00 to $6.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. Finally, HC Wainwright dropped their target price on shares of Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Friday, November 7th.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Nisa Investment Advisors LLC raised its position in Sana Biotechnology by 673.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 10,911 shares of the company’s stock valued at $30,000 after purchasing an additional 9,501 shares during the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in shares of Sana Biotechnology during the third quarter worth $36,000. TD Waterhouse Canada Inc. acquired a new stake in shares of Sana Biotechnology in the third quarter valued at $37,000. Lyell Wealth Management LP bought a new position in shares of Sana Biotechnology in the third quarter valued at about $37,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in shares of Sana Biotechnology in the third quarter valued at about $39,000. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Stock Performance

NASDAQ:SANA opened at $3.93 on Friday. The company has a 50-day moving average of $4.31 and a 200-day moving average of $4.14. Sana Biotechnology has a 52 week low of $1.26 and a 52 week high of $6.55. The company has a market capitalization of $1.05 billion, a price-to-earnings ratio of -4.05 and a beta of 1.96.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.16) earnings per share (EPS) for the quarter. Sell-side analysts forecast that Sana Biotechnology will post -1.16 EPS for the current year.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.